1.
Liu Y, Dong C, He X, Shu Y, Wu P, Zou J. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. J Pharm Pharm Sci [Internet]. 2022 Dec. 21 [cited 2024 Mar. 28];25:377-90. Available from: https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/33020